



Medicine: lanadelumab (brand name: Takhzyro®) for hereditary angioedema

Shire, part of Takeda UK Ltd

What is lanadelumab for?

Lanadelumab is used to prevent attacks of hereditary angioedema (HAE). HAE is a rare inherited condition, which causes swelling that can affect any part of the body including the hands, feet, arms, legs, intestines, face and throat. Attacks are unpredictable and can be life threatening in cases where the swelling around the throat presses against the airway. Lanadelumab is for patients who are 12 years or older.

How does lanadelumab work?

People with HAE have high levels of a substance called bradykinin in their bloodstream. Lanadelumab blocks the activity of an enzyme (called kallikrein) that raises the levels of bradykinin in the blood. This may help to reduce the amount of bradykinin in the bloodstream and prevent symptoms of HAE.

What has SMC said?

SMC has accepted lanadelumab for the prevention of HAE attacks as described above. This acceptance is restricted to use in patients who have HAE type I or II, who would otherwise be considered for long-term treatment with a medicine called a C1-esterase inhibitor.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, applying extra flexibility because lanadelumab is a medicine for a rare condition and after receiving a confidential discount from the company, SMC was able to accept it as a possible preventative treatment within NHSScotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that lanadelumab for use as described above is the right medicine for you, you should be able to have your treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisation below can provide more information and support for people with HAE and their families. SMC is not responsible for the content of any information provided by external organisations.

HAE UK



<http://www.haeuk.org/>



07975 611787

You can find out more about lanadelumab in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 9 December 2019

SMC No: (SMC2206)